DKC1: A Drug Target / Disease Biomarker (G1736)

Target Name: DKC1

NCBI ID: G1736

DKC1

DKC1: A Drug Target / Disease Biomarker

DKC1, also known as heat shock protein 1, is a protein that is expressed in a variety of tissues and cells throughout the body. It is a key regulator of the stress response, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of DKC1 is its role in the heat shock response, which is a critical mechanism that helps the body to respond to and recover from stress, such as increased temperatures, exercise, or the exposure to toxins. DKC1 helps to regulate the production of proteins that are involved in the heat shock response, and it also helps to coordinate the response of cells to stress.

In addition to its role in the heat shock response, DKC1 is also involved in a number of other processes in the body, including:

* Cell signaling and communication: DKC1 has been shown to be involved in the regulation of cell signaling and communication, and it is thought to play a key role in the development of cancer.
*Immun response: DKC1 is involved in the regulation of the immune response, and it has been implicated in the development of autoimmune disorders.
*Hormonal regulation: DKC1 is involved in the regulation of hormone signaling, and it is thought to play a key role in the development of some forms of cancer.

DKC1 is also a potential drug target, and several studies have suggested that it may be a useful target for the treatment of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting DKC1 is to use small molecules, such as drugs that can inhibit the activity of DKC1, to reduce the production of proteins that are involved in the heat shock response and the immune response. This approach is thought to be effective because DKC1 is a protein that is involved in a number of important processes in the body, and it is difficult to target specific proteins without disrupting the overall function of the body.

Another approach to targeting DKC1 is to use antibodies, such as those that are designed to recognize and selectively bind to DKC1. This approach is thought to be effective because antibodies are specific and can be used to target a protein that is involved in a variety of different processes in the body, and can be used to treat a variety of diseases.

Overall, DKC1 is a protein that is involved in a number of important processes in the body, and it is a potential drug target for the treatment of a variety of diseases. Further research is needed to fully understand the role of DKC1 in the body and its potential as a drug target.

Protein Name: Dyskerin Pseudouridine Synthase 1

Functions: Catalytic subunit of H/ACA small nucleolar ribonucleoprotein (H/ACA snoRNP) complex, which catalyzes pseudouridylation of rRNA (PubMed:25219674). This involves the isomerization of uridine such that the ribose is subsequently attached to C5, instead of the normal N1 (PubMed:25219674). Each rRNA can contain up to 100 pseudouridine ('psi') residues, which may serve to stabilize the conformation of rRNAs. Required for ribosome biogenesis and telomere maintenance (PubMed:19179534, PubMed:25219674). Also required for correct processing or intranuclear trafficking of TERC, the RNA component of the telomerase reverse transcriptase (TERT) holoenzyme (PubMed:19179534)

The "DKC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DKC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets